[Percutaneous tumor ablation therapy for the advanced stage of HCC].
We have performed percutaneous tumor ablation (PTA) including percutaneous ethanol injection therapy (PEIT) for 90% of the patients with hepatocellular carcinoma. Until December 1998, the 793 patients received PTA, 5 years survival rate reached 39.8%. Excluding the patients with Child C whose hepatic function were extremely low, 5 years survival rate reached to the level of 41.2%. Since 5 years survival rate in stage IV-A reached 24.4%, the patients of stage IV-A may be considered to have an indication for PTA. We have confirmed the effectiveness of the local treatment including radiotherapy for advanced hepatocellular carcinoma with portal vein invasion. We are attempting to perform PTA for the extra-hepatic lesions that had no indication of other treatment. However the indication of PTA is limited by the presence of diffuse nodules, exacerbation of the hepatic function, or tumor invasion to portal vein, bile duct, inferior vena cava.
Teratani
T
T
Dept. of Gastroenterology, University of Tokyo, Japan.
Shiina
S
S
Obi
S
S
Hamamura
K
K
Koike
Y
Y
Akamatsu
M
M
Fujishima
T
T
Tateishi
R
R
Imai
Y
Y
Shiratori
Y
Y
Omata
M
M
D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery*; D017115:Catheter Ablation; D000431:Ethanol / Q000008:administration & dosage*; D006801:Humans; D015552:Injections, Intralesional; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery*; D015996:Survival Rate
D000431:Ethanol